Skip to main content

Advertisement

Table 3 Summary of all AEs in at least 20% of subjects in any treatment arm (safety population)

From: Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling

  Arm 1 trastuzumab N = 32a Arm 2 lapatinib N = 34 Arm 3 trastuzumab + Lapatinib N = 31a
Any AE, n (%) 31 (97) 34 (100) 31 (100)
Diarrhea 17 (53) 29 (85) 31 (100)
Nausea 26 (81) 26 (76) 27 (87)
Rash 14 (44) 28 (82) 26 (84)
Fatigue 22 (69) 24 (71) 24 (77)
Alopecia 21 (66) 23 (68) 18 (58)
Neutropenia 15 (47) 12 (35) 16 (52)
Neuropathy peripheral 15 (47) 19 (56) 14 (45)
Anemia 10 (31) 12 (35) 12 (39)
Hypokalaemia 2 (6) 10 (29) 11 (35)
Epistaxis 7 (22) 10 (29) 10 (32)
Dysgeusia 4 (13) 10 (29) 9 (29)
Myalgia 4 (13) 10 (29) 9 (29)
Pyrexia 3 (9) 8 (24) 9 (29)
Vomiting 7 (22) 15 (44) 9 (29)
Mucosal inflammation 6 (19) 7 (21) 8 (26)
Nail disorder 4 (13) 10 (29) 8 (26)
Cough 8 (25) 3 (9) 7 (23)
Headache 8 (25) 6 (18) 7 (23)
Decreased appetite 5 (16) 7 (21) 7 (23)
Dyspepsia 6 (19) 5 (15) 7 (23)
Dyspnea 4 (13) 6 (18) 7 (23)
Edema peripheral 5 (16) 10 (29) 7 (23)
Stomatitis 5 (16) 7 (21) 7 (23)
Arthralgia 5 (16) 11 (32) 6 (19)
Constipation 12 (38) 8 (24) 6 (19)
Pruritus 3 (9) 7 (21) 6 (19)
  1. Abbreviation: AE adverse event.
  2. a1 patient in the trastuzumab arm and 2 patients in the trastuzumab + lapatinib arms did not receive therapy and therefore were not included in the safety population.